AU3579200A - Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1 - Google Patents

Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1

Info

Publication number
AU3579200A
AU3579200A AU35792/00A AU3579200A AU3579200A AU 3579200 A AU3579200 A AU 3579200A AU 35792/00 A AU35792/00 A AU 35792/00A AU 3579200 A AU3579200 A AU 3579200A AU 3579200 A AU3579200 A AU 3579200A
Authority
AU
Australia
Prior art keywords
productionof
extrahepatic
hepatic
insulin
regulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35792/00A
Inventor
Olle Isaksson
John-Olov Jansson
Claes Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SALTECH I GOTEBORG AB
Original Assignee
SALTECH I GOTEBORG AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SE9900708 priority Critical
Priority to SE9900708A priority patent/SE9900708L/en
Priority to SE9903108 priority
Priority to SE9903108A priority patent/SE9903108D0/en
Application filed by SALTECH I GOTEBORG AB filed Critical SALTECH I GOTEBORG AB
Priority to PCT/SE2000/000391 priority patent/WO2000050067A1/en
Publication of AU3579200A publication Critical patent/AU3579200A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
AU35792/00A 1999-02-26 2000-02-28 Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1 Abandoned AU3579200A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9900708 1999-02-26
SE9900708A SE9900708L (en) 1999-02-26 1999-02-26 Föefarande and composition for regulating hepatic and extrahepatic production of insulin-like growth factor-1
SE9903108 1999-09-01
SE9903108A SE9903108D0 (en) 1999-09-01 1999-09-01 Effect of systemic liver derived IGF-1 for the Treatment of Obesity
PCT/SE2000/000391 WO2000050067A1 (en) 1999-02-26 2000-02-28 Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1

Publications (1)

Publication Number Publication Date
AU3579200A true AU3579200A (en) 2000-09-14

Family

ID=26663518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35792/00A Abandoned AU3579200A (en) 1999-02-26 2000-02-28 Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1

Country Status (2)

Country Link
AU (1) AU3579200A (en)
WO (1) WO2000050067A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3494A1 (en) 2001-01-05 2002-07-11 Pfizer Anti-receptor antibodies i like growth factor insulin
EP1506286B1 (en) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
CA2545755A1 (en) 2003-11-12 2005-05-26 Schering Corporation Plasmid system for multigene expression
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp therapeutic combinations of anti- IGFR1
US7811562B2 (en) 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4238493A (en) * 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
JPH08508296A (en) * 1993-04-07 1996-09-03 アムジエン・ブルダー・インコーポレーテッド How to use the insulin-like growth factor binding protein
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
EP0871475A2 (en) * 1995-09-14 1998-10-21 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
DK0771817T3 (en) * 1995-10-30 2003-07-28 Oleoyl Estrone Developments S Oleatmonoestere of estrogens for the treatment of obesity and / or overweight

Also Published As

Publication number Publication date
WO2000050067A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
AU757936C (en) Controlled detachment stents
DE60036290D1 (en) Pyrazol derivatives and method for the production thereof and pesticides containing these as active ingredients
DE60027310D1 (en) Method for the continuous coating of rubber-material material
DE60014162D1 (en) Galenic compositions containing fenofibrate and method for the production thereof
AU2002246846A1 (en) Coating for implantable devices and a method of forming the same
AU1469201A (en) Hyperbranched polyol macromolecule, method of making same, and coating composition including same
PL397734A1 (en) Application of herbicide composition, method for controlling weeds and herbicide formulation
PL350796A1 (en) Compositions for promoting growth
EP1107791B8 (en) Hydrogel compositions for the controlled release administration of growth factors
AU4175400A (en) Self-assembled monolayer and method of making
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
GB2347927B (en) Organic anti-reflective coating material and its preparation
AT285883T (en) Method for powdering a form and a coating powder therefor
PL343605A1 (en) Preparation of organic acids
AU5890800A (en) Dental anti-hypersensitivity composition and method
AU1144201A (en) Implant for osteosyntheses
AU2829501A (en) Method of model construction
AU5276600A (en) Kit for flushing medical devices and method of preparing the flushing solution
AU6587000A (en) Composition
IL142068A (en) Compositions containing a derivative of hyaluronic acid and methods for the preparation thereof
AU7861200A (en) Powder coating compositions
AUPP155998A0 (en) Coating composition
AU1870099A (en) Stabilised insulin compositions
DE69923692D1 (en) Growth hormone releasing oxindol derivatives
AU7989400A (en) Compounds and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase